Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.Autor: cancerGRACE - H. Jack West, MD

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.Autor: cancerGRACE - H. Jack West, MD

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.Autor: cancerGRACE - H. Jack West, MD

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.Autor: cancerGRACE - H. Jack West, MD

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.Autor: cancerGRACE - H. Jack West, MD

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.Autor: cancerGRACE - H. Jack West, MD

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.Autor: cancerGRACE - H. Jack West, MD

NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.Autor: cancerGRACE - H. Jack West, MD

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.Autor: cancerGRACE - H. Jack West, MD

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.Autor: cancerGRACE - H. Jack West, MD

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.Autor: cancerGRACE - H. Jack West, MD

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.Autor: cancerGRACE - H. Jack West, MD

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.Autor: cancerGRACE - H. Jack West, MD

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.Autor: cancerGRACE - H. Jack West, MD

Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.Autor: cancerGRACE - H. Jack West, MD

Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.Autor: cancerGRACE - H. Jack West, MD

The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.Autor: cancerGRACE - H. Jack West, MD

The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.Autor: cancerGRACE - H. Jack West, MD

Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.Autor: cancerGRACE - H. Jack West, MD

Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.Autor: cancerGRACE - H. Jack West, MD

"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).Autor: cancerGRACE - H. Jack West, MD

"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).Autor: cancerGRACE - H. Jack West, MD

Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.Autor: cancerGRACE - H. Jack West, MD

Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.Autor: cancerGRACE - H. Jack West, MD

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.Autor: cancerGRACE - H. Jack West, MD

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.Autor: cancerGRACE - H. Jack West, MD

Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.Autor: cancerGRACE - H. Jack West, MD

Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.Autor: cancerGRACE - H. Jack West, MD

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.Autor: cancerGRACE - H. Jack West, MD

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.Autor: cancerGRACE - H. Jack West, MD

Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.Autor: cancerGRACE - H. Jack West, MD

Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.Autor: cancerGRACE - H. Jack West, MD

Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.Autor: cancerGRACE - H. Jack West, MD

Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.Autor: cancerGRACE - H. Jack West, MD

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.Autor: cancerGRACE - H. Jack West, MD

EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.Autor: cancerGRACE - H. Jack West, MD

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.Autor: cancerGRACE - H. Jack West, MD

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.Autor: cancerGRACE - H. Jack West, MD

Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.Autor: cancerGRACE - H. Jack West, MD

Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.Autor: cancerGRACE - H. Jack West, MD

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.Autor: cancerGRACE - H. Jack West, MD

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.Autor: cancerGRACE - H. Jack West, MD

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.Autor: cancerGRACE - H. Jack West, MD

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.Autor: cancerGRACE - H. Jack West, MD

Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?Autor: cancerGRACE - H. Jack West, MD

Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?Autor: cancerGRACE - H. Jack West, MD

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.Autor: cancerGRACE - H. Jack West, MD

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.Autor: cancerGRACE - H. Jack West, MD

Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.Autor: cancerGRACE - H. Jack West, MD

Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.Autor: cancerGRACE - H. Jack West, MD